CI

At a glance

ClinicalIndex Comparison Record
Phase 3Recruiting· 650 target
Drug / intervention
Curcumin +1 moredrug
Likely dose
Curcumin 500mgfrom record
Key inclusion· 8
  • ✓Status post radical prostatectomy for histologically confirmed adenocarcinoma of the prostate
  • ✓Pathologically confirmed T1-T3 disease without lymph node or metastatic disease
  • ✓Low-risk disease: Gleason 6 or 7 (T2 disease) with PSA <20
  • ✓ECOG performance status 0-2
Key exclusion· 11
  • ✕More than 3 months from surgery to enrollment
  • ✕T3b, T4, or node-positive disease
  • ✕Macroscopic residual disease after surgery
  • ✕Prior hormone therapy before surgery

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02064673
NCT02064673Phase 3RecruitingOn TrackUpdated 3mo ago
Long Recruiting
CompareCT.gov

Randomized Trial of Adjuvant Curcumin After Prostatectomy

yair lotan·interventional·Posted Feb 17, 2014·Updated Mar 30, 2026

In Brief

A Phase 3 clinical trial evaluating Curcumin and placebo for Prostate Cancer. Currently recruiting, targeting 650 participants across 1 site.

Detailed Summary

This is a prospective study to determine if the adjuvant use of Curcumin improves recurrence-free survival.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 3Recruiting
2014201520162017201820192020202120222023202420252026202720282029
First PostedFeb 17, 2014
Enrollment StartMay 1, 2014
Primary CompletionJun 1, 2028
Study CompletionDec 1, 2028
TodayJul 2, 2026
Enrollment to primary: 14.1 yearsPosted 12.4 years agoPrimary completion in 1.9 years

Interventions

Curcumindrug

Curcumin or placebo 500mg by mouth twice a day for 6 months

placebodrug

placebo orally twice a day